Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2021

Aug 02, 2021

SELL
$18.04 - $22.09 $956 - $1,170
-53 Reduced 5.81%
860 $28,000
Q1 2021

May 06, 2021

SELL
$16.59 - $33.89 $371,815 - $759,542
-22,412 Reduced 96.09%
913 $28,000
Q4 2020

Feb 10, 2021

SELL
$27.5 - $37.92 $18.8 Million - $25.9 Million
-683,743 Reduced 96.7%
23,325 $1.01 Million
Q3 2020

Nov 12, 2020

BUY
$34.44 - $43.75 $376,808 - $478,668
10,941 Added 1.57%
707,068 $38.1 Million
Q2 2020

Aug 12, 2020

BUY
$27.12 - $45.97 $14,075 - $23,858
519 Added 0.07%
696,127 $42.5 Million
Q4 2019

Feb 10, 2020

SELL
$46.96 - $61.67 $130 Million - $170 Million
-2,760,208 Reduced 79.87%
695,608 $61 Million
Q3 2019

Nov 07, 2019

SELL
$59.47 - $93.1 $45.7 Million - $71.5 Million
-767,718 Reduced 18.18%
3,455,816 $317 Million
Q2 2019

Aug 08, 2019

SELL
$75.84 - $105.21 $19.4 Million - $26.9 Million
-255,567 Reduced 5.71%
4,223,534 $537 Million
Q1 2019

May 01, 2019

SELL
$64.44 - $104.11 $3.22 Million - $5.21 Million
-50,022 Reduced 1.1%
4,479,101 $0
Q4 2018

Feb 14, 2019

SELL
$59.1 - $93.26 $6.76 Million - $10.7 Million
-114,405 Reduced 2.46%
4,529,123 $449 Million
Q3 2018

Nov 13, 2018

SELL
$88.86 - $117.49 $17.8 Million - $23.5 Million
-199,871 Reduced 4.13%
4,643,528 $678 Million
Q2 2018

Jul 17, 2018

SELL
$99.64 - $127.59 $19.8 Million - $25.3 Million
-198,668 Reduced 3.94%
4,843,399 $760 Million
Q1 2018

May 10, 2018

SELL
$105.8 - $150.94 $15.5 Million - $22.1 Million
-146,368 Reduced 2.82%
5,042,067 $861 Million
Q4 2017

Feb 13, 2018

SELL
$81.25 - $130.7 $10.7 Million - $17.2 Million
-131,767 Reduced 2.48%
5,188,435 $924 Million
Q3 2017

Oct 20, 2017

SELL
$57.74 - $91.42 $4.65 Million - $7.36 Million
-80,456 Reduced 1.49%
5,320,202 $731 Million
Q2 2017

Aug 10, 2017

BUY
N/A
5,400,658
5,400,658 $567 Million

Others Institutions Holding BLUE

About bluebird bio, Inc.


  • Ticker BLUE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 77,121,800
  • Market Cap $29.3M
  • Description
  • bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes transformative gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include betibeglogene autotemcel for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell ...
More about BLUE
Track This Portfolio

Track Baillie Gifford & CO Portfolio

Follow Baillie Gifford & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Baillie Gifford & CO, based on Form 13F filings with the SEC.

News

Stay updated on Baillie Gifford & CO with notifications on news.